July 26th, 2017 by aveciapharma
Nitto Denko Avecia Inc. (Avecia) has announced the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in Milford, MA. The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the Milford, MA facility. The ceremony will open with remarks from:
- Hideo Takasaki, CEO, Nitto Denko Corporation
- Jay Ash, MA Secretary for the Executive Office of Housing and Economic Development, followed by keynotes from:
- Mark Alles, CEO, Celgene Corporation
- Barry Greene, President, Alnylam Pharmaceuticals
The expansion will add 20,000 square feet of manufacturing and office space at Avecia's Milford, MA site and provide CGMP oligonucleotide manufacturing capacity up to 1.8mol. The total capacity of Avecia's Milford, MA site has now more than doubled up to 3.0mol, which makes Avecia in Milford, MA the largest oligonucleotide manufacturing site in the world.
Posted in: Company News